UNRESECTABLE RENAL CELL CARCINOMA
Clinical trials for UNRESECTABLE RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gut bacteria booster may help kidney cancer drugs work better
Disease control OngoingThis early-phase trial is testing whether adding a probiotic called CBM588 to the standard combination of cabozantinib and nivolumab can improve treatment for advanced or metastatic kidney cancer. The probiotic is designed to restore helpful gut bacteria that may help the immune …
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New immune cell therapy trial for advanced cancers withdrawn before starting
Disease control TerminatedThis early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could fasting 14 hours a night help cancer immunotherapy work better?
Knowledge-focused TerminatedThis study aimed to see if limiting food intake to a 10-hour window each day (with 14 hours of nightly fasting) could improve how well immunotherapy works in people with advanced head/neck or kidney cancer. Researchers planned to track changes in gut bacteria and immune markers. …
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC